Loading…
Hebei TCM maker famous for Lianhua Qingwen, a widely used cold and respiratory-infection remedy in China.
Hebei TCM maker famous for Lianhua Qingwen, a widely used cold and respiratory-infection remedy in China.
Sells traditional Chinese medicine mostly as branded over-the-counter and prescription products through pharmacies and hospitals, with Lianhua Qingwen the product that carries the company and its sales spiking when respiratory illness spreads. Tongxinluo, a heart remedy, is a second pillar.
In one line: A Chinese TCM cold-remedy maker (like a herbal Theraflu).
Moat: narrow (brand). Household-name brand recognition built during respiratory-illness outbreaks including COVID-19.
Headquarters: Shijiazhuang, Hebei, China · Employees: 11,343
Size Shijiazhuang Yiling Pharmaceutical (002603.SZ) is a China Health Care company (Pharmaceuticals: Other) with a market value of $4.02B, the 635th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥16.05 on 6 Nov 2026.
Performance Over six months the shares fell 5.8%, against -1.5% for the median peer and -16.4% for the China market (cap-weighted) — 9th lowest of 21 in its peer set.
Growth Revenue grew 31.9% over the last twelve months (peer median +6.1%); the operating margin is 21.1% (peer median 15.4%).
Valuation It trades at 18.1× forward earnings against a peer median of 18.6× (8th cheapest of 16).
Price implies For today's price to make sense, revenue must grow about -3% a year for seven years (Req g). Recent delivered growth is -2%, so the hurdle is -1 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 12.4 points above its cost of capital (6.1% WACC).
Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥7.93B | CN¥7.76B | CN¥6.46B | CN¥10.2B | CN¥12.4B |
| Revenue growth | — | +20% | -37% | -17% | — |
| Gross profit | CN¥5.64B | CN¥4.77B | CN¥3.01B | CN¥5.65B | CN¥7.63B |
| EBITDA | n/a | CN¥1.95B | -CN¥391M | CN¥2.16B | CN¥3.31B |
| Net income | CN¥1.38B | CN¥1.29B | -CN¥725M | CN¥1.35B | CN¥2.36B |
| Free cash flow | CN¥1.91B | CN¥1.53B | CN¥438M | -CN¥118M | CN¥3.28B |
| Capital expenditure | CN¥212M | CN¥246M | CN¥290M | CN¥311M | CN¥214M |
| Total debt | CN¥21.1M | CN¥25.7M | CN¥76.5M | CN¥2.14B | CN¥1.45B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Shijiazhuang Yiling Pharmaceutical 002603.SZ | $4.02B | -6% | +32% | 21% | 18.1× | -3.2% |
| Tasly Pharmaceutical 600535.SS | $3.20B | -5% | -4% | 19% | 16.5× | -7.6% |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | $6.48B | 0% | +4% | 14% | 12.8× | -6.3% |
| Tianjin Chase Sun Pharmaceutical 300026.SZ | $1.32B | -6% | -29% | 3% | 23.0× | 8.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002603.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +4.3% | +0.5% | 8th highest of 21 |
| 6-month return | -5.8% | -1.5% | 9th lowest of 21 |
| Distance from 52-week high | -25.6% | -19.5% | 7th lowest of 21 |
| Revenue growth (TTM) | +31.9% | +6.1% | highest of 20 |
| Operating margin | 21.1% | 15.4% | 8th highest of 20 |
| Forward P/E | 18.1× | 18.6× | 8th cheapest of 16 |
| Growth the price implies (Req g, 7 yrs) | -3.2% | 1.8% | 5th least demanding of 19 |
| Growth delivered (Del g) | -2.2% | +6.1% | lowest of 19 |
| Hurdle (Req g minus delivered) | -1.0 pp | -6.2 pp | 7th most demanding of 19 |
| ROIC minus cost of capital | +12.4 pp | +2.7 pp | 3rd highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shijiazhuang Yiling Pharmaceutical 002603.SZ | China | $4.02B | -6% | +32% | 21% | 18.1× | -3.2% | -2.2% |
| Dong-E-E-Jiao 000423.SZ | China | $4.80B | -8% | +8% | 29% | 17.1× | -4.6% | +14.5% |
| Guangdong Zhongsheng Pharmaceutical 002317.SZ | China | $3.13B | +35% | -14% | 9% | 80.3× | 34.7% | +5.9% |
| Bausch Health Companies BHC.TO | Canada | $3.09B | +48% | +10% | 27% | 1.9× | -14.5% | +5.9% |
| Jilin Aodong Pharmaceutical 000623.SZ | China | $3.02B | -9% | -4% | -13% | n/a | 5.2% | +1.0% |
| By-health 300146.SZ | China | $2.61B | -1% | +10% | 11% | 25.0× | 5.1% | +0.6% |
| China Resources Double-Crane Pharmaceutical 600062.SS | China | $2.50B | -10% | -1% | 13% | 9.8× | -8.3% | +5.3% |
| China Resources Jiangzhong Pharmaceutical 600750.SS | China | $2.19B | -3% | -10% | 24% | 15.7× | -2.5% | +11.6% |
| Abivax ABVX.PA | France | $7.58B | -25% | n/a | n/a | n/a | n/a | n/a |
| Granules India GRANULES.NS | India | $2.10B | +8% | +22% | 17% | 24.9× | 23.5% | +10.6% |
| Health and Happiness (H&H) International 1112.HK | Hong Kong | $2.05B | +70% | +24% | 16% | 12.6× | -3.0% | +4.4% |
| China Meheco 600056.SS | China | $2.00B | -14% | +2% | 3% | n/a | -0.8% | -2.1% |
| Porton Pharma Solutions 300363.SZ | China | $1.92B | +14% | +6% | -2% | n/a | 5.3% | +10.4% |
| Lupin LUPIN.NS | India | $9.65B | -19% | +24% | 24% | 20.9× | 8.8% | +13.0% |
| Tibet Cheezheng Tibetan Medicine 002287.SZ | China | $1.66B | -15% | -7% | 28% | n/a | -1.1% | +10.4% |
| Zhejiang Medicine 600216.SS | China | $1.61B | -23% | -6% | 7% | 11.3× | -6.7% | +3.9% |
| Bora Pharmaceuticals 6472.TW | Taiwan | $1.55B | -2% | -6% | 15% | 14.2× | 4.5% | +60.2% |
| Guilin Sanjin Pharmaceutical 002275.SZ | China | $1.53B | +27% | -3% | 24% | 18.6× | -2.2% | +5.5% |
| Aurobindo Pharma AUROPHARMA.NS | India | $10.9B | +22% | +14% | 15% | 22.4× | 21.0% | +6.3% |
| Sudeep Pharma SUDEEPPHRM.NS | India | $1.41B | +75% | +27% | 33% | 67.7× | n/a | n/a |
| Jamieson Wellness JWEL.TO | Canada | $1.35B | +35% | +15% | 15% | 21.2× | 11.0% | +15.3% |